<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Identify and Resolve Cell Therapy Batch Manufacturing Exceptions</title><link>/community-hubs/deltav-community-connect/b/ops-weblog/posts/identify-and-resolve-cell-therapy-batch-manufacturing-exceptions-680521848</link><description>We conclude our series on improving cell therapy manufacturing with a closer look at the review by exception process.
 
 In the manufacturing process of cell therapeutics, product cycle times are extremely short and any exceptions occurring during the</description><dc:language>en-US</dc:language><generator>Telligent Community 13</generator></channel></rss>